You are here:

Moxifloxacin (Avelox®)

Advice

Recommended for restricted use within NHS Scotland

REASONS FOR ADVICE

Moxifloxacin (Avelox), a new fluoroquinolone antibiotic, should be reserved as a second line treatment for community acquired pneumonia in accordance with British Thoracic Society (BTS) and Scottish Intercollegiate Guidelines Network (SIGN) guidance.

Drug Details

Drug Name: Moxifloxacin (Avelox®)
SMC Drug ID: 69/03
Manufacturer: Bayer plc/Bayer Schering Pharma
Indication: Community acquired pneumonia
BNF Category:
Submission Type: Full submission
Status: Restricted
Date Advice Published: 13 October 2003

Back